https://www.thebodypro.com/collection/hepatitis-c

Featured

Hepatitis C Drug News: Odalasvir + AL-335 + Simeprevir Img
Hepatitis C

Hepatitis C Drug News: Odalasvir + AL-335 + Simeprevir

Phase 2a results were announced in a study to understand the safety and to determine an effective dose of the combination of odalasvir, AL-335 with and without simeprevir to treat HCV genotype 1 treatment-naive patients.

Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System Img
Hepatitis C

Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System

"The Veterans Affairs Healthcare system is a perfect place to test for 'real world' results," Alan Franciscus writes. "How do the direct-acting antiviral drugs work in a 'real world' setting as opposed to clinical trials?"

Hepatitis C Drug News: 3-Week Response-Guided Therapy Img
Hepatitis C

Hepatitis C Drug News: 3-Week Response-Guided Therapy

An important study was recently published in Lancet Gastroenterology & Hepatology holds the promise of changing the way that people with hepatitis C are treated.

Consequences of Inaccurate Hepatitis C Virus Genotyping on the Costs of Prescription of Direct Antiviral Agents in an Italian District Img
Hepatitis C

Consequences of Inaccurate Hepatitis C Virus Genotyping on the Costs of Prescription of Direct Antiviral Agents in an Italian District

Researchers conducted a study to analyze commercial hepatitis C genotype/subtype assays to understand the cost-effectiveness of potential errors in the assays.

How I Nearly Outed Someone's Hepatitis C Status: A Cautionary Tale Img
Hepatitis C

How I Nearly Outed Someone's Hepatitis C Status: A Cautionary Tale

"Not only is nothing private on the internet, it is forever," Lucinda K. Porter, R.N., writes. "Information cannot be erased from the web. So, if you don't want people to know about your having hepatitis C, don't tell anyone."

Hepatitis C Cure Rates High With Daclatasvir/Sofosbuvir Regardless of Antiretroviral Regimen Img
Hepatitis C

Hepatitis C Cure Rates High With Daclatasvir/Sofosbuvir Regardless of Antiretroviral Regimen

Type of antiretroviral regimen did not affect sustained virologic response 12 weeks after therapy stopped (SVR12) in a 12-week trial of daclatasvir/sofosbuvir (DCV/SOF).

Real-World Hepatitis C Cure Rates Higher With 2 Direct Acting Agents Img
Hepatitis C

Real-World Hepatitis C Cure Rates Higher With 2 Direct Acting Agents

Among patients coinfected with hepatitis C (HCV) and HIV, sustained virologic response 12 weeks after HCV therapy ended (SVR12) was significantly higher with simeprevir (SMV) and sofosbuvir (SOF, Sovaldi) plus ribavirin (RBV) than with SOF/RBV in a t...

No Man Is an Island: Hepatitis C in Rural Southern Indiana, Part 1 Img
Hepatitis C

No Man Is an Island: Hepatitis C in Rural Southern Indiana, Part 1

"Health disparities can act a bit like compound interest," Matthew Zielske writes. "Each new health or socioeconomic concern that arises will be added to the existing pool of problems which will lead to further tangling the knot."

High HCV Levels in 33% of Semen Samples From Men With HIV and HCV Img
Hepatitis C

High HCV Levels in 33% of Semen Samples From Men With HIV and HCV

One third of gay or bisexual men infected with HIV and hepatitis C virus had detectable HCV in their semen.

Newer Guidelines Widen Statin Treatment Gap in HIV and HCV-Positive Veterans Img
Hepatitis C

Newer Guidelines Widen Statin Treatment Gap in HIV and HCV-Positive Veterans

Mark Mascolini reports on a new study comparing statin indications in male veterans with HIV, HCV or both with three sets of cholesterol guidelines and examining why almost one-third of statin-eligible veterans were not getting the drugs.